| | Business Summary | | Amersham
plc,
formerly
known
as
Nycomed
Amersham
plc,
is
engaged
in
in
vivo
diagnostic
imaging,
with
products
for
the
diagnosis
and
treatment
of
disease,
and
in
life
sciences,
with
products
for
use
in
the
discovery
and
development
of
drugs.
Amersham
and
its
subsidiary
constitute
an
international
group
engaged
in
the
research
and
development,
production,
sale,
distribution
and
licensing
of
medical
imaging
contrast
media
and
radiotherapy
through
its
imaging
business.
The
Company
is
also
engaged
in
the
research
and
development,
manufacture
and
sale
of
specialized
products
and
services
for
life
science
research
through
American
Pharmacia
Biotech.
Amersham
is
currently
organized
into
two
principal
lines
of
business:
the
medical
imaging
business
and
the
life
sciences
business. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Amersham
plc
is
engaged
in
the
world-wide
development,
manufacture
and
sale
of
specialized
products
for
research-based
biotechnology
supply
and
for
the
diagnosis
and
treatment
of
disease.
For
the
six
months
ended
6/30/01,
revenues
increased
22%
to
L738.5
million.
Net
income
before
U.S.
GAAP
adjustment
increased
51%
to
L86.8
million.
Revenues
reflect
increased
demand.
Net
income
also
reflects
lower
cost
of
goods
sold
as
a
percentage
of
revenues. | | More
from
Market Guide: Significant
Developments |
| | Officers | | | FY1999 Pay | |
| Richard Lapthorne, 56
Chairman | $99K | William Castell, 52
CEO | 447K | Robert Allnutt, 45
Sec. | -- | | Dollar
amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/n/nye.gif)